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Abstract
Background: DC derived-exosomes are nanomeric vesicles harboring functional MHC/peptide
complexes capable of promoting T cell immune responses and tumor rejection. Here we report
the feasability and safety of the first Phase I clinical trial using autologous exosomes pulsed with
MAGE 3 peptides for the immunization of stage III/IV melanoma patients. Secondary endpoints
were the monitoring of T cell responses and the clinical outcome.
Patients and methods: Exosomes were purified from day 7 autologous monocyte derived-DC
cultures. Fifteen patients fullfilling the inclusion criteria (stage IIIB and IV, HLA-A1+, or -B35+ and
HLA-DPO4+ leukocyte phenotype, tumor expressing MAGE3 antigen) were enrolled from 2000 to
2002 and received four exosome vaccinations. Two dose levels of either MHC class II molecules
(0.13 versus 0.40 × 1014 molecules) or peptides (10 versus 100 µg/ml) were tested. Evaluations
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were performed before and 2 weeks after immunization. A continuation treatment was performed
in 4 cases of non progression.
Results: The GMP process allowed to harvest about 5 × 1014 exosomal MHC class II molecules
allowing inclusion of all 15 patients. There was no grade II toxicity and the maximal tolerated dose
was not achieved. One patient exhibited a partial response according to the RECIST criteria. This
HLA-B35+/A2+  patient vaccinated with A1/B35 defined CTL epitopes developed halo of
depigmentation around naevi, a MART1-specific HLA-A2 restricted T cell response in the tumor
bed associated with progressive loss of HLA-A2 and HLA-BC molecules on tumor cells during
therapy with exosomes. In addition, one minor, two stable and one mixed responses were
observed in skin and lymph node sites. MAGE3 specific CD4+ and CD8+ T cell responses could not
be detected in peripheral blood.
Conclusion: The first exosome Phase I trial highlighted the feasibility of large scale exosome
production and the safety of exosome administration.
Background
Immunization protocols rely on the capacity of the vac-
cine design to elicit long term protective, peptide specific,
MHC restricted-CD4+ and CD8+ T cell responses in cancer
patients. In preclinical studies, few vaccination strategies
were shown to counteract tumor induced-tolerance and to
promote immunity to cancer leading to tumor eradication
[1]. One of the most promising approach recently devel-
opped is based on the adoptive transfer of mature den-
dritic cells (DC) pulsed with tumor peptides and control
antigen [2,3]. Dhodapkar et al. performed a pionnering
clinical trial demonstrating the rapid generation of T cell
immunity against recall antigens and Keyhole Limpet
Hemocyanin in normal volunteers [4] and Schüler-
Thurner et al. successfully promoted active, melanoma
peptide-specific, IFNγ  producing, effector CD8+ T cells
[5,6] and helper CD4+ Th1 lymphocytes [6] in the major-
ity of patients with metastatic melanoma. If a single injec-
tion of CD34+ progenitor derived-DC vaccine can lead to
induction of T cell immunity [7], correlations between
clinical responses and CTL Tc1/CD4+ Th1 activation have
been rarely reported [8-10]. Therefore, it is conceivable
that antigen spreading initiated by the specific T cells and/
or intervention of alternate effectors also elicited by
mature DC [11,12] might account for this apparent
discrepancy.
DC process exogenous antigens in endosomal compart-
ments such as multivesicular endosomes [13] which can
fuse with plasma membrane, thereby releasing antigen
presenting vesicles called «exosomes» [14-16]. Exosomes
are 50–90 nm diameter vesicles containing antigen pre-
senting molecules (MHC class I, class II, CD1, hsp70–90)
tetraspan molecules (CD9, CD63, CD81), adhesion mol-
ecules (CD11b, CD54) and CD86 costimulatory mole-
cules [17-19] i.e the necessary machinery required for
generating potent immune responses. Exosomal MHC
class I and II /peptide complexes are functional but
require to be transferred to naive DC [20-23] to promote
T cell activation leading to tumor eradication [16,21].
Exosomes pulsed with tumor peptides are more efficient
than peptides alone and as efficient as mature DC for the
priming of MART1 -specific CTL and for tumor growth
inhibition in the HLA-A2 transgenic mouse model [21].
The molecular characterization of DC derived-exosomes
[24,25] and the definition of quality control parameters
for exosome purification and storage [26] allowed to con-
duct a Phase I clinical trial aimed at evaluating the feasa-
bility of exosome harvesting from autologous monocyte
derived-DC cultures and the safety of exosome inocula-
tion in melanoma patients. Secondary endpoints were the
immunomonitoring of peptide specific CD4+ and CD8+ T
cell responses restricted by exosomal MHC class II and I
molecules respectively. Up to 41 ± 6.7 (9–115) id/sc vac-
cinations/patient at the lowest dosage (i.e 0.13 × 1014 exo-
somal MHC class II molecules /vaccine) could be
generated for all patients from one leukapheresis. One
partial response and some other tumor regressions at skin
and lymph node sites even in tumors that did not respond
to other vaccine formulations were observed in the
absence of toxicity. A case report of MART1 antigen
spreading and MHC class I loss variant suggested that exo-
somes mediated bioactivity in vivo, supporting to conduct
Phase II clinical trials.
Patients, Material and Methods
Protocol design, Patients' characteristics and eligibility 
criteria
We report here about the first phase I trial (Fig. 1) which
administers 4 exosome vaccinations intradermally and
subcutaneously at 1 week intervals (Fig. 2). The study was
approved by the Ethics Committee, local IRBs and regula-
tory authorities, and informed written consent was given
by all patients. The authors were in compliance with the
Helsinki Declaration. Fifteen patients bearing melanoma
fullfilling the inclusion criteria were enrolled in the studyJournal of Translational Medicine 2005, 3:10 http://www.translational-medicine.com/content/3/1/10
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(see Additional file 1 and Table 1). Inclusion criteria were:
biopsy-proven American Joint Committee on Cancer
stage IIIB and IV metastatic melanoma, HLA-A1+, or -B35+
and HLA-DPO4+ phenotype (as defined by serological
and molecular typing), tumor expressing MAGE3 antigen
(assessed by RT-PCR, as described elsewhere [27,28]),
inclusion at least 4 weeks after cytotoxic chemotherapy,
surgery, or radiation therapy, intradermal skin test positiv-
ity to one or more recall antigens using Pasteur Mérieux
multi DTH test, age > 18 years, Karnofsky performans sta-
tus >80%, lymphocyte counts >1000 /mm3. Exclusion cri-
teria were: prior chemotherapy or biotherapies <4 weeks
before trial entry, brain metastasis, pregnancy, concurrent
steroids or immunosuppressive therapy, history of
asthma, congestive heart failure, autoimmune disease,
active infections. Three patients presenting with skin or
LN involved sites declined conventional therapies and
received exosomes upfront (see Additional file 1 and
Table 1). Patients received a 4 week outpatient vaccina-
tion course with antigen loaded DC derived-exosomes
given intradermally (1/10th) and subcutaneously (9/10th)
every week for a total of 4 vaccinations (Fig. 2). The injec-
tion sites were rotating between both thighs and forearms.
The study was scheduled in two steps i.e 1) MHC class I
peptide loading was «indirectly» performed on the DC
culture at 10 µg/ml, and 2) MHC class I peptide loading
was «directly» performed onto purified and acid eluted
exosomes (Fig. 1). Indeed, our preclinical studies aimed at
comparing the exosome immunogenicity after indirect
versus direct peptide loading showed a superiority of the
Study design Figure 1
Study design. Different weeks (W) of the study are described. Screening, HLA typing and tumor evaluation were performed 
within 2 weeks before lymphapheresis. DTH (Multi Mérieux skin test) was performed at the time of lymphapheresis, and exo-
some vaccine started 3 weeks later.Journal of Translational Medicine 2005, 3:10 http://www.translational-medicine.com/content/3/1/10
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latter process [20,22]. Exosomes (quantified as concentra-
tions of MHC class II molecules, see below) or peptides
that were pulsed onto exosomes were administered in a
dose escalation design. In the first step, 0.13 or 0.40 × 1014
MHC class II molecules were inoculated in a cohort of
three patients each. In the second step, the concentration
of peptide loading onto exosomes varied from 10 µg/ml
to 100 µg/ml in a cohort of 3 and 6 patients respectively
(see Additional file 1 and Table 1).
Clinical grade exosome production
MD-DC propagation
Based on size and density, we could rapidly purify exo-
somes from monocyte derived-DC (MD-DC) culture
supernatants according to a good manufacturing process
already described [26]. Briefly, the adherent fraction of
peripheral blood mononuclear cells (PBMC) from a leu-
kapheresis is replenished with fresh medium (AIMV
media discarded from haptoglobin and albumin through
a 500 kDa MWCO hollow fiber cartridge ultrafiltration
(UFP-500-C-4A from A/G Technology, Needham, MA)
followed by sterile filtration through a 0.22 um Sartopore
Schema of exosome purification processes Figure 2
Schema of exosome purification processes. Exosomes were purified from monocyte derived-DC (MD-DC) culture 
supernatants according to a good manufacturing process already described [26]. In the second part of the trial, indirect loading 
of MHC class II peptides (MAGE3247–258.DP04, KKLLTQHFVQENYLEY) was performed on DC cultures followed, after exo-
some purification by a direct loading of MHC class I (MAGE3168–176.A1/B35; EVDPIGHLY) peptides at 10 or 100 µg/ml at pH 
4.2 [22]. Quality control parameters included dosing of exosomal MHC class II molecules, flow cytometry analyses and func-
tional assays using superantigens as described in material and methods.
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2 membrane) containing rhuGM-CSF (50 ng/ml,
Immunex, Seattle, WA) and rhu IL-4 (250 IU/ml, Schering
Plough, Kennilsworth, NJ) until day 7.
Clinical grade exosome purification
Exosomes secreted in the supernatant of MD-DC cultures
(1–4 liters) were purified to 175 fold the starting volume
according to a GMP method previously described [26].
MHC class I peptide loading of exosomes
This method has been previously described [21,22].
Briefly, the indirect loading of peptides was performed for
both MHC class I (Mage3168–176.A1/B35; EVDPIGHLY)
and MHC class II peptides (Mage3247–258.DP04, KKLL-
TQHFVQENYLEY) in pharmaceutical quality (Multiple
Peptide Systems, San Diego, CA) at 10 µg/ml at day 6 of
the MD-DC culture and the exosomes were purified from
day 7 culture supernatant as described above. The direct
loading of MHC class I peptides at pH 4.2 has been
reported [22].
Quality control parameters for exosome inoculation
Insurance quality criteria allowing exosome release in
patients were qualitative (expression of CD81 tet-
raspanins), quantitative (at least 1 × 1014 MHC class II
molecules in immunocapture assays) and included a
functional assay (bioactivity in the superantigen SEE test
of potency).
Quantitation of exosome MHC class II concentration by adsorption 
ELISA and immunophenotyping
These methods have been previously described [26].
Test of potency
The bioactivity of exosomal MHC class II molecules was
tested using a superantigen bioassay. Exosomes were incu-
bated with femtoM dosages of SEE and washed by density
cushion. SEE harboring exosomes were pulsed onto Raji
cells. Exosome pulsed Raji cells were subjected to Jurkat
cell lines that produced IL-2 in response to SEE. IL-2 con-
centrations in the supernatants of the Raji/Jurkat cocul-
tures were assessed using a commercial IL-2 ELISA kit.
Clinical monitoring
Adverse events were graded according to the WHO Toxic-
ity criteria. All patients underwent assessment of tumor
status at baseline and 2 weeks after the fourth exosome
vaccination. Tumor evaluation was performed using the
RECIST criteria. Disease progression was defined as >20%
increase in target lesions and/or the appearance of new
lesions, partial response as a > 30% decrease in the sum of
the longest diameters of target lesions.
Immunomonitoring assays
Pre-, per- and post-immunization PBMCs were collected
before vaccination (week 0, 5% of total leukocytes col-
lected from the starting leukapheresis), after 2 (week 4, 50
ml heparinized blood sample) and 4 vaccines (week 7, by
leukapheresis), isolated by Ficoll density gradient and
conditioned either for immediat testing or kept frozen for
further analyses. In patient #12, single cell suspensions
from dissociated cervical lymph nodes resected at the end
of the induction and retreatment phases were also
collected.
Immunophenotyping
Determination of peripheral lymphocytes subsets were
performed by four color immunostainings using combi-
nations of FITC-, PE-, Cychrome-, APC-labeled mAbs
directed against CD2, CD3, CD4, CD5, CD8, CD19,
CD25, CD27, CD45RA, CD56, CD69, CD122, HLA-DR
(all purchased from Becton Dickinson, Pont de Claix, FR).
Table 1: Formulation of Product
Dose Groups Peptides loaded / HLA class Peptide loading method and 
concentration
DEX dose (expressed as numbers 
of MHC class II molecules)
A MAGE A3 (168–176) / class I Indirect (10 µg/mL) 0.13 × 1014
MAGE A3 (247–258) / class II Indirect (10 µg/mL)
tetanus toxoid / class II Indirect (10 µg/mL)
B MAGE A3 (168–176) / class I Indirect (10 µg/mL) 0.4 × 1014
MAGE A3 (247–258) / class II Indirect (10 µg/mL)
C MAGE A3 (168–176) / class I Direct (10 µg/mL) 0.13 × 1014
MAGE A3 (247–258) / class II Indirect (10 µg/mL)
tetanus toxoid / class II Indirect (10 µg/mL)
D MAGE A3 (168–176) / class I Direct (100 µg/mL) 0.13 × 1014
MAGE A3 (247–258) / class II Indirect (10 µg/mL)Journal of Translational Medicine 2005, 3:10 http://www.translational-medicine.com/content/3/1/10
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Controls included isotype-matched immunoglobulins.
Thawed PBMCs were stained for 15 min at 4°C, washed
twice and fixed in 1X PBS with 0.1% paraformaldhehyde.
Ten thousand viable PBMCs were acquired on a FACSCal-
ibur cytometer (Becton Dickinson, BDIS, San Jose, CA,
USA) according to standard FSC/SSC criteria and analyzed
with the Cellquest software.
Peptides and recall antigens for functionnal assays
Reactivity of PBMCs was assessed in response to
MAGE3168–176.A1/B35, MAGE3247–258.DP04 (Multiple
Peptide System), and control viral peptides (HIV/nef113–
128.A1, HIV/nef73–82.B35, FLU/pb1591–599.A1, FLU/np265–
274.A2, EBV/bzlf154–64.B35, EBV/bmlf1259–267.A2, CMV/
pp65495–503.A2 TT/p2830–844, Eurogentec, Seraing, BEL)
used according to the HLA classe I phenotype of patients,
as well as, against tetanus anatoxin (at 100, 10 and 1 µg/
ml), tuberculin (at 50, 5 and 0.5 IU/ml), and phytohe-
maglutinin (at 2.5, 0.5, and 0.1 µg/ml, PHA HA16, Murex
Biotech, Dartford, UK).
Proliferation assays
Fresh PBMCs (2 × 105 cells/well) were cultured in tripli-
cates in presence of graded doses of peptides (at 50, 5, and
0.5 µg/ml) or control antigens or medium alone. Prolifer-
ative capacity was determined after overnight pulsing with
[3H]thymidine (1µCi/well, NEN, Paris, France) at day 5 of
the coculture (earlier at day 3 for PHA). Cells were har-
vested onto 96-well Unifilter microplates, dried overnight
and radioactivity counted on a microplate scintillation
counter (TopCount-NXT, Packard, CA, USA). All determi-
nations were made in triplicate wells and data were calcu-
lated as means ± SEM of cpm.
Enzyme-linked Immunospot assays
ELISPOT assay for the detection of antigen-specific IFNγ -
producing T cells was performed as described previously
[29]. Briefly, fresh or frozen PBMCs (5 × 105cells/well)
were cultured in triplicate in nitrocellulose-bottomed 96-
well plates (MAHA S4510, Millipore, Saint Quentin- en-
Yvelines, FR) precoated with 2 µg/ml of a primary anti-
IFNγ  mAb (1-D1K, Mabtech, Hamburg, GER) in presence
of peptides (at 5 µg/ml) or control antigens in RPMI1640
medium supplemented with 8% human AB serum. After
incubation for 48 hrs, wells were washed five times and
incubated with a secondary biotinylated anti-IFNγ  mAb
(7-B6-1, Mabtech) for 2 h, washed and stained using an
extravidine-alkaline phosphatase conjugate substrate kit
(Biorad, Hercules, CA, USA). Spots were evaluated and
counted using a computer-assisted video imaging analyser
(Bioreader 2000, Biosys, Karben, GER).
Microcultures for semiquantitative detection of Mage3.A1/B35 CTL 
precursors
The microculture method developed by Coulie et al. [30]
was used to assessed CTL precursors specific for
MAGE3.A1/B35 peptide. Briefly, groups of 2 × 105 pep-
tide-pulsed PBMC (20 µg/ml) were cultured in Iscove's
medium with 10% human AB serum supplemented with
IL-2 (20 IU/ml), IL-4 (10 ng/ml) and IL-7 (10 ng/ml) and
restimulated at day 7 with replacement of 50% fresh
medium with addition of MAGE3.A1/B35 peptide (10 µg/
ml). On day 15, microcultures were screened for specific
CD8+ T cells using the relevant MAGE3.A1 or B3501
tetramers coupled to PE together with a control APC
labeled-HLA-A1 containing an influenza peptide (all
tetramers kindly given by D. Colau, Ludwig Institut for
Cancer Research, Brussels, BE). This microculture proce-
dure was also applied on patient #12's tumor infiltrating
LN to highlight CD8+ T cells specific for HLA-A2/
MART126–35, and HLA-B3501/MAGE3168–176. Flow
cytometry acquisition and analysis of tetramer positive
cells were performed as recommanded by P. Coulie [30].
Immunohistochemistry on lymph node tissues
Immunostainings were performed on sections obtained
from formalin-fixed and paraffin-embedded lymph node
samples. Sections were deparaffinized, placed in 10
mmol/L Na-citrate buffer (pH.7), and heated in a micro-
wave during 20 min. Endogenous peroxidase was blocked
with 1% hydrogen peroxide in methanol for 30 min.
Slides were stained using anti-CD3 and anti-CD57 mAb
(Pharmingen, France) and secondary antibodies with
appropriate controls.
Results
Feasability of exosome production in advanced melanoma 
patients
Leukaphereses of 1.5 blood mass performed in the 15
metastatic melanoma patients enrolled in the study
allowed the recovery of 9.7 × 109 ± 0.8 PBMC (range: 4.4–
15) containing 20.7% ± 1.8 CD14+ cells (range: 12.4–
33.0). These monocytes differentiated into immature MD-
DC in rhu GM-CSF and rhu IL-4 (means: 313 × 106 ± 100,
range: 50–1200) as assessed at day 7 in flow cytometry
highlighting loss of CD14 molecules, acquisition of
CD1a, poor cell surface expression of CD83. In 3 patients
out of 15, the first leukapheresis did not allow CD14+ cells
to adhere and consequently, a second leukapheresis was
required to harvest exosomes. The GMP process allowed
to purify a mean of about 5.22 × 1014 ± 0.9 (range: 1.2–
15.0) exosomal MHC class II molecules from superna-
tants of day 6 to day 7 MD-DC required for up to 41 ± 6.7
(9–115) id/sc vaccinations/patient at the lowest dosage
(i.e 0.13 × 1014 exosomal MHC class II molecules /vac-
cine). As for the patients who benefited from continua-
tion treatment requiring a second leukapheresis (pt #3,Journal of Translational Medicine 2005, 3:10 http://www.translational-medicine.com/content/3/1/10
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#12 and #14), the second exosome recovery was not sig-
nificantly different from the first one. The quality control
parameters required for GMP exosome batch release are
reminded in M&M.
GMP exosomes were successfully produced from DC cul-
tures derived from all melanoma patients enrolled in this
phase I study, allowing at least 4 exosome inoculations.
Safety and clinical outcome
No major (>grade II) toxicity was observed. A grade 1
fever was recorded in 5 patients. We noted slight inflam-
matory reactions at vaccine sites without outward delayed
type hypersensitivity reactions. Some patients (#4, #8,
#11, #12 and #15) reported a transient swelling and sen-
sitivity of cutaneous and lymph nodes metastases 48 hrs
after each exosome inoculation.
Among the six patients vaccinated in the first part of the
study, only one patient (#3) presenting with a stage III dis-
ease exhibited a minor response (disappearance of one sc
lesion out of 3). This patient benefited from a continua-
tion therapy with exosomes every other 3 weeks for 21
months and remained stable for up to24 months. It is
noteworthy that this patient was progressing despite vac-
cination with MAGE3 protein prior to enrollment in the
Phase I exosome trial. In the second part of the study
(«direct loading»), responses were only observed in the
second group of patients receiving the highest dosages of
peptides (100 µg/ml) pulsed onto exosomes. One female
patient (#12) presenting with five supraclavicular invaded
lymph nodes after conventional chemotherapy (DTIC, 2
cycles) exhibited a partial response (PR) after the induc-
tion therapy. Interestingly, disappearance of arterial neo-
vasculature concomittant with tumor shrinkage and
necrosis as assessed by doppler pulsed ultrasonography
could be demonstrated (Fig. 3). Halo of depigmentation
around neavi appeared 10 months after the initiation of
vaccination (Fig. 3). A continuation therapy with exo-
somes was administered for 4 months every other 3 weeks
allowing stabilisation without toxicity supporting the
indication of surgery that confirmed the partial response
(Jul. 2002, Fig. 3) followed by a second leukapheresis
allowing to pursue vaccination for 10 months. This
patient relapsed in contralateral nodes six months after
exosomes discontinuation but exhibited a slow pace of
tumor growth. Two additionnal patients (#11, #14) pre-
senting with only skin and /or LN lesions exhibited tran-
sient stabilisation and started a continuation therapy.
Interestingly, patient # 14 who displayed a SD with exo-
somes had previously progressed despite biotherapy with
IFNα  and vaccination with poxviruses recombinant for
the MAGE 3A1 cDNA. It is of note that patient #9 in a M1b
stage exhibited a regression on a subcutaneous nodule but
did progress in the pulmonary sites (mixed response).
Exosome therapy promoted 2 stable diseases, 1 minor
response, 1 partial response and 1 mixed response in skin
or LN sites even in patients progressing with biotherapies
or alternate vaccines. Patient #3 and #12 with respectively
minor and partial responses are still alive. Neither of these
patients exhibited a delayed type hypersensitivity
response to the immunizing epitopes after the completion
of the 4 vaccines.
T cell immunomonitoring
The phenotypic analyses of lymphocyte subsets did not
reveal any significant changes in the percentages nor abso-
lute counts following exosome therapy (not shown).
Interestingly, the CD122 molecule i.e IL-2Rβ  chain was
upregulated in both CD4 and CD8 T cell subsets after exo-
some therapy (p < 0.05 using Student t'test, week 7 versus
week 1 for CD4+ T cells). Serial ex vivo ELISPOT analyses
of PBMC before (W1, Fig. 4A) and after (W7, Fig. 4B) exo-
some vaccination did not reveal any significant Th1
(using TT or DP04 MAGE 3 peptides) or Tc1 (using MAGE
3. A1/B35 peptides) type immune responses induced by
exosomes. Recall responses (proliferative responses to TT
protein using autologous DC or restimulation with autol-
ogous DC pulsed with MAGE 3.DP04) did not allow to
conclude that exosomes boosted MHC class II specific
responses at these time points (not shown). In accordance
with these findings, the skin reactivities to iterative injec-
tions of id/sc exosomes did not correspond to clinically
significant Delayed Type Hypersensitivity responses.
Extensive immunomonitoring by screening of 15 day-
microcultures of MAGE3 peptide pulsed PBMC per-
formed in the presence of IL-2, IL-4, IL-7 [30] using the
MAGE3.A1/B35 tetramers allowed to detect and clone
specific CTL precursors only in 3 patients (#3, 9 and 11)
but estimated at a low frequency (10-6 - 10-7 of the CD8+ T
cells). These studies did not allow to conclude for signifi-
cant anti-MAGE3A1/B35 CTL responses induced by exo-
some therapy nor to suggest the clonal expansion of
discrete T cell specificities (not shown) in patients' periph-
eral blood.
Comprehensive analyses of a partial response
Patient#12 presenting with five supraclavicular lymph
nodes exhibited a partial regression after 4 exosome vac-
cines in November 2001 and underwent a continuation
therapy from Jan. 2002 to April 2002 (Fig. 3). The HLA
class I haplotype of the patient was A2.A26.B35.B44 and
the initial tumor sites expressed both MAGE1, MAGE3
and other melanoma antigens such as Melan-A/MART1
and NA-17 (as assessed using semiquantitative RT-PCR).
The antitumor effects did not correlate with an enhanced
frequency of MAGE3 specific CTL precursors as demon-
strated using microculture detection assays after the first 4
vaccines or after the continuation treatment (not shown).
However, tumor shrinkage after the continuation therapyJournal of Translational Medicine 2005, 3:10 http://www.translational-medicine.com/content/3/1/10
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prompted a partial surgical resection in July 2002 and
comprehensive analyses of tumor infiltrating
lymphocytes (TILN) and tumor cells in 4 avalaible sites
(#1, 3, 5, 6 in Fig. 3). Site 5 was scored tumor free by the
pathologists. Site 1 and 3 maintained the transcription of
Mage3 mRNA. In these TILN sites, detection of HLA-A2/
MART126–35, -/gp100209M-217 -/Tyrosinase239–251 and HLA-
B3501/MAGE3168–176 -specific CD8+ lymphocytes using
soluble fluorescent tetramers were performed directly
ex_vivo and after microculture restimulation assays using
MART126–35 or MAGE3 peptides.Only high frequencies of
MART1 specific CD8+ T cells were detected in TILN from
site 1 and 6 (1.22 and 0.85 % respectively) and in periph-
eral blood (0.53% in May 2002 versus 0.15% in Oct.
Clinical outcome of patient #12 during exosome-based vaccination Figure 3
Clinical outcome of patient #12 during exosome-based vaccination. This patient presented with progressive supracla-
vicular lymph nodes containing MAGE3 expressing tumor cells in July 2001 when enrolled in the exosomes Phase I trial starting 
in October 2001. She underwent a first leukapheresis for exosomes production and vaccination (weekly injections in Nov. 
2001 during induction therapy and from January 2002 to April 2002 on a three week basis in continuation treatment). The ini-
tial size of the target LN are indicated on the left and were followed up by doppler pulsed ultrasonography from Nov 2001 to 
Dec 2001 (sizes indicated on the right side at the end of the induction therapy). Continuation therapy with exosomes was indi-
cated and maintained clinical stability until the last available exosome dose in Jul. 2002, when she underwent surgery for lym-
phadenectomy. Results obtained by the pathologists are indicated (N+ if node is invaded by tumor cells, N- if not, MAGE3+ as 
expression of MAGE3 mRNA in RT-PCR). A second leukapheresis was performed on Aug. 2002 allowing a second therapy 
with exosomes on a 3 week basis that was continuated until Jul 2004. Six months after exosomes discontinuation (Oct 2004), 
the patient relapsed in contralateral LN and presented with one lung metastasis.
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Evaluation of Tc1/Th1 immune responses to melanoma and viral/recall antigens Figure 4
Evaluation of Tc1/Th1 immune responses to melanoma and viral/recall antigens. A. Before exosome vaccination 
(W1). B. After exosome inoculation (W7). PBMC obtained at baseline (W1) and after 4 exosome injections are cultured 48 h 
with the immunizing melanoma antigens i.e Mage 3.A1/B35 or Mage3.DP04 (5 µg/ml) or with viral/recall control antigens 
(FluMP.A1, HIV.A1, EBV.B35, tetanus anatoxin, tuberculin) or with PHA. The three first patients were also assayed with the 
universal MHC class II restricted TT peptide. The specific T cell response in each of the evaluated patients is expressed as the 
number of IFNγ  spot forming unit/5 × 105 PBMC.
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2001) that were confirmed by expansion in all microcul-
ture assays (Fig. 5A and 5B). In parallel, halo of depig-
mentation around naevi appeared (Fig. 3). Moreover, a
cell line established from site 1 (CUR1) did not express
the HLA-A2 allele in flow cytometry using the MA2.1mAb
but maintained the expression of HLA-BC molecules (Fig.
5C). In November 2003 while disease was slowly
progressive, another LN was removed allowing to re-
establish another cell line (CUR2) that no longer express
HLA-BC molecules (as assessed in flow cytometry using
W6.32 or anti-HLA-BC mAb, Fig. 5C).
Immunohistochemistry performed on the primary (April
2001) and secondary (July 2002) tumor specimen
revealed quantitative modifications of tumor infiltrating
CD3+CD57+ T cells. While activated T cells were mostly
surrounding the tumor bed initially, a two fold expansion
or recruitment of activated T cells invade tumor areas after
exosome vaccines (Fig. 6).
Discussion
This work is reporting for the first time the feasability and
safety of DC derived-exosome-based vaccination in
Antigen spreading and MHC class I loss variant in patient#12 Figure 5
Antigen spreading and MHC class I loss variant in patient#12. Flow cytometry analyses on serial blood specimen (A) 
or tumor invaded lymph nodes (B) gating on CD8+ T lymphocytes stained using A2/Mart1 or A2/gag specific fluorescent 
tetramers. Ex vivo microcultures stimulated with Mart1 peptides and examined according to similar settings. (C) Flow cytome-
try analyses of two CUR tumor cell lines (pt#12) after the first exosome therapy (continuation treatment) in clinical response 
and after the second exosome course (second leukapheresis) at relapse for MHC class I (anti-HLA-A2 mAb, anti-HLA-BC mAb 
and W6.32 Ab) expression. A positive control was included which consisted of a allogeneic HLA-A*0201melanoma line FON.
Jul02 (CUR1)
Oct01 Dec01 May02 Dec01 microculture
0.15% 0.12% 0.53%
25.4%
A. PBMCs
B. TILN 
C. TUM Cell Lines
MHC class I
(W6.32)
HLA-A2
(MA2.1)
HLA-B/C
(B1.23.2)
A
2
/
M
a
r
t
1
-
P
E
Site 1 (N+) Site 6 (N+)
1.22 0.85
A
2
/
M
a
r
t
1
-
P
E
A
2
/
g
a
g
-
P
E
CD8-FITC
CD8-FITC
Nov03 (CUR2)
100 101 102 103 104
M1 M2
M3
100 101 102 103 104
M1 M2
M3
100 101 102 103 104
M1 M2
M3
Iso. Ctl Ab CUR
CUR
FONJournal of Translational Medicine 2005, 3:10 http://www.translational-medicine.com/content/3/1/10
Page 11 of 13
(page number not for citation purposes)
melanoma patients. From a single leukapheresis, up to
1014-1015 exosomal MHC class II molecules could be puri-
fied in GMP conditions for all patients, allowing 9–123
sc/id vaccinations with 0.13 × 1014 exosomal MHC class II
molecules. The optimal dosages of exosomal MHC class II
molecules required to trigger an efficient peptide-specific
CTL response leading to tumor rejection was about 1010-
1011  molecules in preclinical studies in the HLA-A2
transgenic mouse model [21]. The optimal method for
pulsing exosomal MHC class I molecules with peptides
was a direct loading after acid elution of the exosomal pel-
let [20,22]. A dose response was observed in vitro,
prompting the use of 100 ug/ml for peptide pulsing onto
GMP exosomes. As to MHC class II associated-peptide
loading, pulsing immature day 5 DC with 10 ug/ml was
optimal [22]. However, in this Phase I study, since no
untoward clinical effect nor pharmacodynamic parameter
appear to be dose-dependent, neither the peptide pulsing
method nor the dosage of exosomes or peptides could
help defining the maximal tolerated doses of exosomes.
Interestingly, in the second Phase I trial initiated at the
Dukes' University in unresectable lung carcinoma, there
was a trend for a better efficacy of exosomes directly
pulsed with MHC class I peptides in long term survival
[31].
Only one objective response (PR) according to the RECIST
criteria was recorded. However, one minor response and
two stabilisations prompted the continuation of treat-
ment as well. Tumor regression was exclusively observed
in skin and lymph node lesions, as already reported for
peptide-based vaccines [32]. It is noteworthy that three of
these patients had primarily resisted to alternate immuno-
therapy strategies (i.e IFN type I, ALVAC-Mage 3, Mage 3
protein) but it is also likely that such immunomodulators
might have facilitated exosome efficacy. However, we
were not able to detect significant Mage 3 specific CTL
precursors in peripheral blood (nor lymph nodes and
lesions) after exosome vaccination. Notewithstanding,
MHC class I tumor loss variant and naevi depigmentation
was observed in one case (pt #12), suggesting melanoma
antigen spreading mediated by HLA-A2-restricted CTL
cells. It is conceivable that the Mart1-specific CTL moni-
tored in blood and in LN TIL could have mediated part of
these antitumor effects.
No DTH responses to iterative inoculations of exosomes
or MHC class II restricted-direct or recall responses (to TT
epitopes (3 pts tested), or Mage DP04 epitopes (12
patients tested)) were detected at 4 and 6 weeks of exo-
some vaccination. It is noteworthy that peptides and not
whole proteins (such as TT or KLH) were used to pulse DC
in vitro, in contrast to what has been reported in most DC
trials. However, in the transgenic Marilyn mouse model
[23], id inoculation of I-Ab harboring exosomes pulsed
with H-Y epitopes could promote expansion of peptide
specific CD4+ transgenic T cells. Nevertheless, MHC class I
restricted-CTL responses elicited by exosomes pulsed with
Mart1 peptides in HLA-A2 transgenic mice were dramati-
cally boosted by adjuvants [21]. Therefore, it is conceiva-
ble that injection of exosomes in the area of an
inflammatory draining lymph node harboring mature
APC might promote elicitation of T cell immune
responses leading to tumor regressions in patients. Alter-
natively, we recently showed that regulatory C4+CD25+ T
cells (Treg) restrict T cell responses elicited by DC derived-
exosomes (Chaput et al, in preparation). Therefore, high
yields of Treg at start might severely impair the efficacy of
exosomes to prime or boost T cell responses. Supporting
this view, our unpublished data demonstrate synergistic T
Lymphocyte recruitment and activation in patient#12's  melanoma Figure 6
Lymphocyte recruitment and activation in 
patient#12's melanoma. T cells that were double-stained 
by anti-CD3 and anti- CD57 mAb were counted in 2 sections 
of 6 lymph nodes available from the lymph node dissection 
specimen obtained before (A. April 2001) and after (B. July 
2002) treatment (cf Fig. 3). Counts were performed in 12 
sections in total as follows: cells that were double-stained by 
CD3 and CD57 were counted on the whole section includ-
ing B cell areas, and the total count was reported to 1 mm2. 
Results showed an increase of the CD3+CD57+ cells after 
treatement (mean = 122/mm2) as compared to the count 
before treatment (mean: 58/mm2).
A.
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cell dependent-antitumor effects between peptide pulsed-
exosomes and immunopotentiating dosing of
cyclophosphamide.
Since no specific CD4+ or CD8+ T cells generated by the
exosome vaccines could be detected and could account for
the tumor regression in patient#12, what could have been
the primary effectors accounting for antigen spreading?
We were able to show enhanced NK cell effector functions
following exosome administration in peripheral blood of
8/13 patients including patient #12 for whom CD3-
CD57+ cells expressing PEN5 (mostly expressed on
CD56dim NK cells) were markedly infiltrating the tumor
after therapy (N. Chaput, manuscript in preparation).
Therefore, it is conceivable that DC derived-exosomes
from melanoma patients are specifically endowed with
NK cell stimulatory capacity in vivo. This hypothesis
deserves further investigations and should be pursued in
the next clinical studies. Moreover, since our preclinical
data in tumor bearing mice highlighted a critical role of
suppressor T cells in restricting exosome-mediated specific
T cell responses, T regulatory cells should be monitored
and combination of cyclophosphamide together with
exosomes could be invisioned (N. Chaput, in prepara-
tion). Phase II/III trials will address the potential of exo-
somes to enhance time to progression in advanced non
small cell lung carcinoma patients.
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